SESSION 1999

1

HOUSE BILL 1095

Short Title: Clinical Pharmacist Practitioner.

(Public)

Sponsors: Representatives Allen; and Cansler.

Referred to: Finance.

April 15, 1999

| 1 | A BILL TO BE ENTITLED |
|----|---|
| 2 | AN ACT AUTHORIZING THE LICENSURE OF CLINICAL PHARMACIST |
| 3 | PRACTITIONERS. |
| 4 | The General Assembly of North Carolina enacts: |
| 5 | Section 1. G.S. 90-6 reads as rewritten: |
| 6 | "§ 90-6. Regulations governing applicants for license, examinations, etc.; |
| 7 | appointment of subcommittee. |
| 8 | (a) The North Carolina Medical Board is empowered to prescribe such regulations |
| 9 | as it may deem proper, governing applicants for license, admission to examinations, the |
| 10 | conduct of applicants during examinations, and the conduct of examinations proper. |
| 11 | (b) The North Carolina Medical Board shall appoint and maintain a subcommittee |
| 12 | to work jointly with a subcommittee of the Board of Nursing to develop rules and |
| 13 | regulations to govern the performance of medical acts by registered nurses, including the |
| 14 | determination of reasonable fees to accompany an application for approval not to exceed |
| 15 | one hundred dollars (\$100.00) and for renewal of approval not to exceed fifty dollars |
| 16 | (\$50.00). The fee for reactivation of an inactive incomplete application shall be five |
| 17 | dollars (\$5.00). Rules and regulations developed by this subcommittee from time to time |
| 18 | shall govern the performance of medical acts by registered nurses and shall become |
| 19 | effective when adopted by both the North Carolina Medical Board and the Board of |

| 1 | Nursing. The 1 | North Carolina Medical Board shall have responsibility for securing |
|----|-------------------|---|
| 2 | compliance with | n these regulations. |
| 3 | * | North Carolina Medical Board shall appoint and maintain a subcommittee |
| 4 | | l physicians to work jointly with a subcommittee of the North Carolina |
| 5 | | macy to develop rules and regulations to govern the performance of |
| 6 | medical acts by | licensed pharmacists, including the determination of reasonable fees to |
| 7 | accompany an a | application for approval not to exceed one hundred dollars (\$100.00) and |
| 8 | for renewal of a | approval not to exceed fifty dollars (\$50.00). The fee for reactivation of |
| 9 | | omplete application shall be five dollars (\$5.00). Rules and regulations |
| 10 | developed by t | his subcommittee from time to time shall govern the performance of |
| 11 | medical acts by | licensed pharmacists and shall become effective when adopted by both |
| 12 | | lina Medical Board and the North Carolina Board of Pharmacy. The |
| 13 | North Carolina | Medical Board shall have responsibility for securing compliance with |
| 14 | these regulation | <u>s.</u> " |
| 15 | Section | on 2. G.S. 90-18(c) is amended by adding a new subdivision to read: |
| 16 | "(<u>3a)</u> | The provision of drug therapy management by a licensed pharmacist |
| 17 | | engaged in the practice of pharmacy pursuant to an agreement that is |
| 18 | | physician, pharmacist, patient, and disease specific when performed in |
| 19 | | accordance with rules and regulations developed by a joint |
| 20 | | subcommittee of the North Carolina Medical Board and the North |
| 21 | | Carolina Board of Pharmacy and approved by both Boards." |
| 22 | | on 3. Article 1 of Chapter 90 of the General Statutes is amended by |
| 23 | adding a new se | |
| 24 | | nitations on clinical pharmacist practitioners. |
| 25 | · · · · | person who is licensed under the provisions of G.S. 90-18(c)(3a) to |
| 26 | - | al acts, tasks, and functions may use the title 'clinical pharmacist |
| 27 | | ny other person who uses the title in any form or holds himself or herself |
| 28 | | ical pharmacist practitioner or to be so licensed shall be deemed to be in |
| 29 | violation of this | |
| 30 | | cal pharmacist practitioners are authorized to implement predetermined |
| 31 | | nodify prescribed drug dosages, dosage forms and dosage schedules, and |
| 32 | | tory tests pursuant to a drug therapy management agreement that is |
| 33 | | nacist, patient, and disease specific under the following conditions: |
| 34 | <u>(1)</u> | The North Carolina Medical Board and Board of Pharmacy have |
| 35 | | adopted regulations developed by a joint subcommittee governing the |
| 36 | | approval of individual clinical pharmacist practitioners to practice drug |
| 37 | | therapy management with such limitations that the Board determines to |
| 38 | | be in the best interest of patient health and safety. |
| 39 | <u>(2)</u> | The clinical pharmacist practitioner has current approval from both |
| 40 | | Boards. |
| 41 | <u>(3)</u> | The North Carolina Medical Board has assigned an identification |
| 42 | | number to the clinical pharmacist practitioner which is shown on written |
| 43 | | prescriptions written by the clinical pharmacist practitioner. |

| 1 | (\mathbf{A}) | The draw the many means and a mean and much this the substitution of a |
|----|-------------------------|---|
| 1 | <u>(4)</u> | The drug therapy management agreement prohibits the substitution of a |
| 2 | | chemically dissimilar drug product by the pharmacist for the product |
| 3 | | prescribed by the physician without the consent of the physician and |
| 4 | | includes a policy for periodic review by the physician of the drugs |
| 5 | | modified pursuant to the agreement or changed with the consent of the |
| 6 | (a) $C1$ | physician. |
| 7 | | al pharmacist practitioners in hospitals and other health facilities that |
| 8 | | lished pharmacy and therapeutics committee or similar group that |
| 9 | | prescription drug formulary or other list of drugs to be utilized in the |
| 10 | • | ermines procedures to be followed when considering a drug for inclusion |
| 11 | | y and procedures to acquire a nonformulary drug for a patient may order |
| 12 | | <u>I tests under the following conditions:</u> |
| 13 | <u>(1)</u> | The North Carolina Medical Board and Board of Pharmacy have |
| 14 | | adopted regulations governing the approval of individual clinical |
| 15 | | pharmacist practitioners to order medications and tests with such |
| 16 | | limitations as the Boards determine to be in the best interest of patient |
| 17 | (-) | health and safety. |
| 18 | <u>(2)</u> | The clinical pharmacist practitioner has current approval from both |
| 19 | | Boards. |
| 20 | <u>(3)</u> | The supervising physician has provided to the clinical pharmacist |
| 21 | | practitioner written instructions for ordering, changing, or substituting |
| 22 | | drugs, or ordering tests with provision for review of the order by the |
| 23 | | physician within a reasonable time, as determined by the Boards after |
| 24 | | the medication or tests are ordered. |
| 25 | <u>(4)</u> | The hospital or health facility has adopted a written policy, approved by |
| 26 | | the medical staff after consultation with nursing administrators, |
| 27 | | concerning the ordering of medications and tests, including procedures |
| 28 | | for verification of the clinical pharmacist practitioner's orders by nurses |
| 29 | | and other facility employees and such other procedures that are in the |
| 30 | | best interest of patient health and safety. |
| 31 | • • | drug therapy order written by a clinical pharmacist practitioner or order |
| 32 | | or tests shall be deemed to have been authorized by the physician |
| 33 | ** | e Boards as the supervisor of the clinical pharmacist practitioner, and the |
| 34 | | sician shall be responsible for authorizing the prescription order." |
| 35 | <u>(e)</u> <u>Any 1</u> | registered nurse or licensed practical nurse who receives a drug therapy |
| 36 | order from a cl | linical pharmacist practitioner for medications or tests is authorized to |
| 37 | - | der in the same manner as if the order was received from a licensed |
| 38 | <u>physician.</u> " | |
| 39 | | on 4. G.S. 90-85.3 is amended by adding a new subsection to read: |
| 40 | | cal Pharmacist Practitioner' means a licensed pharmacist who meets the |
| 41 | • | criteria for such title established by the joint subcommittees of the North |
| 42 | Carolina Medica | al Board and the North Carolina Board of Pharmacy and is authorized to |
| | | |

enter into drug therapy management agreements with physicians in accordance with the 1 2 provisions of G.S. 90-18.3."

3

Section 5. G.S. 90-85.3(r) reads as rewritten:

4 'Practice of pharmacy' means the responsibility for: interpreting and evaluating "(r) 5 drug orders, including prescription orders; compounding, dispensing and labeling 6 prescription drugs and devices; properly and safely storing drugs and devices; maintaining proper records; and controlling pharmacy goods and services. A pharmacist 7 8 may advise and educate patients and health care providers concerning therapeutic values, 9 content, uses and significant problems of drugs and devices; assess, record and report 10 adverse drug and device reactions; take and record patient histories relating to drug and device therapy; monitor, record and report drug therapy and device usage; perform drug 11 12 utilization reviews; and participate in drug and drug source selection and device and device source selection as provided in G.S. 90-85.27 through G.S. 90-85.31. A 13 14 pharmacist who has received special training may be authorized and permitted to 15 administer drugs pursuant to a specific prescription order in accordance with rules and regulations adopted by each of the Boards of Pharmacy, the Board of Nursing, and the 16 17 North Carolina Medical Board. Such rules and regulations shall be designed to ensure the 18 safety and health of the patients for whom such drugs are administered. A licensed clinical pharmacist practitioner may collaborate with physicians in determining the 19 20 appropriate health care for a patient, subject to the provisions of G.S. 90-18.3."

Section 6. Article 4A of Chapter 90 of the General Statutes is amended by 21 22 adding a new section to read:

23 "§ 90-85.26A. Clinical pharmacist practitioners subcommittee.

24 The Board of Pharmacy shall appoint and maintain a subcommittee of the Board consisting of four licensed pharmacists to work jointly with the subcommittee of the 25 Board of Medical Examiners to develop rules and regulations to govern the provision of 26 drug therapy management by clinical pharmacist practitioners and to determine 27 reasonable fees to accompany an application for approval or renewal of such approval as 28 provided in G.S. 90-6. The rules developed by this subcommittee shall govern the 29 performance of acts by licensed pharmacists and shall become effective when they have 30 been adopted by both Boards." 31 32

Section 7. This act is effective when it becomes law.